Why invest in CUTISS AG?
CUTISS, a biotech spin-off of the University of Zurich (UZH), has an ambitious vision. We are specialized in the development of personalized, biotechnological skin transplantation products for the treatment of burns, skin defects and extensive scar corrections.
Our lead product, denovoSkin™, has successfully completed Phase I in pediatric patients. Phase II clinical trials are now underway in Europe and Switzerland and are expected to be completed by 2022. The company is also working on the scale-up of the production process by means of automation.
Currently and in the course of a series B financing round that has just been opened, we are looking for new investors with a long-term strategy and a focus on innovation in Life Sciences. Investors that participated in the series A round, closed in June 2018, included, among others, Giammaria Giuliani of Giuliani Pharma, Zürcher Kantonalbank (ZKB), and Yellowstone Holding; CUTISS AG also received funds granted from the European Union (H2020 program), and Innosuisse. For more information, please contact our CEO, Dr. Daniela Marino.